Skylar is an associate editor for The American Journal of Managed Care® (AJMC®) and The Center for Biosimilars®, and joined AJMC® in 2020. She is responsible for covering all aspects of the ever-changing global biosimilar industry and produces content that is accessible and informative for all health care stakeholders.
She has a BA in journalism and media studies from Rutgers University. You can connect with Skylar on LinkedIn.
People With MS Face Higher Rates of Harassment, Criticism at Work Than Healthy Employees
September 24th 2020Patients with multiple sclerosis (MS) reported higher rates of harassment and criticism in the workplace than their healthy counterparts, even after informing employers and coworkers about their diagnosis.
Study: Muscle Loss May Lead to Higher Mortality and Costs for Patients Hospitalized for COPD
August 8th 2020A new study has found that muscle loss can lead to increased rates of mortality and morbidity in patients with chronic obstructive pulmonary disease (COPD). However, one expert remains skeptical whether the study represents the full scope of patients at risk.
Supplemental Process Can Aid in Assessing Value of Rare Disease Treatments
July 25th 2020A study looking at the ways in which different countries handle appraisal and reimbursement processes for rare disease treatments (RDTs) revealed that implementing supplemental processes can aid in patient and physician decision making.
Social Media May Benefit Patients With MS-Associated Depression
July 19th 2020By delivering helpful information and fostering online communities, social media may provide rehabilitation and psychological benefits for patients with multiple sclerosis (MS) who have depression, according to the results of a recent Iranian study.
Gaps Remain Between European Regions for Hemophilia Care Despite Improvements
July 17th 2020Hemophilia care principles have been on the rise in Europe over the course of the last decade, however, differing regions and policies on the continent reveal gaps in access to various treatments and specialty services.
Review Calls For Clear Guidance to Ensure Patient Centricity in Orphan Drug Trials
July 12th 2020Researchers called for new guidance to address the underreporting of patient engagement in rare disease clinical trials after finding a dismal amount of patient-reported outcome measures listed in orphan drug labeling claims.
Authors Call for More Research on Rare Blood Cancers to Fill Knowledge Gaps
July 4th 2020Authors hope that identifying knowledge gaps surrounding rare blood cancers, such as essential thrombocythemia and polycythemia vera, will inspire the science community to invest in new comprehensive research on how to properly diagnose and treat patients.
Combination Therapy More Effective Than Standard Treatment for Rare Blood Disease
June 16th 2020A study conducted by Mayo Clinic researchers revealed that a combined treatment featuring daratumumab in conjunction with the standard-of-care for patients with amyloid light-chain (AL) amyloidosis was more effective in improving the condition than the standard treatment alone.
Immunosuppressive Psoriatic Drugs Don't Increase Risks for COVID-19 Complications
June 13th 2020Authors of an opinion piece concluded that not only are immunosuppressed patients with psoriasis not at an increased risk of developing serious complications related to coronavirus disease 2019 (COVID-19), their medications may help mitigate potential issues.
Orphan Drug Reimbursements Create Tough Situation for South Korean Public Budget
June 12th 2020A data analysis of real-world data found that the rise of orphan drugs (ODs) in the Republic of Korea has not solved all patient accessibility issues as budget concerns can make it difficult to justify reimbursements.
Sociodemographic Factors Influence Outcomes Among Patients With Psoriasis
May 22nd 2020A patient’s sex, disease duration, and residence were the most common sociodemographic factors shown to affect illness acceptance, life satisfaction, sense of stigmatization, and quality of life among those who have psoriasis, according to the results of a recent study.
Pharmacies Adapt in the Wake of Challenges Created by COVID-19, Panel Says
May 15th 2020In light of the coronavirus disease 2019 (COVID-19) pandemic, pharmacies have implemented new strategies to ensure their patients continue to receive care, especially for those who have lost their insurance or have underlying conditions, speakers said this week during the Pharmacy Quality Alliance (PQA) 2020 Annual Meeting.
Expanding Use of Biosimilar Pegfilgrastim Could Save Millions, Study Says
May 10th 2020Expanding access to biosimilar pegfilgrastim (Ziextenzo) for patients at intermediate risk of febrile neutropenia and converting patients at high risk who are on the reference product (Neulasta) could save millions in healthcare costs, according to new study results.
Psoriasis Guidelines From AAD, NPF Spotlight Comorbidities
May 8th 2020Guidelines created by the American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) address care management and treatment options for patients with psoriasis in relation to the increased risk of developing inflammatory, cardiovascular, and metabolic conditions.